XML 71 R57.htm IDEA: XBRL DOCUMENT v3.25.2
Note 11 - Segment Data - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)
$ in Thousands
 3 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Revenues (a): $ 59,543 $ 58,170
Total segment cost of revenues 22,604 20,921
Gross Profit (c) 36,939 37,249
Operating expense 33,875 31,669
Operating income 3,064 5,580
Nonoperating (income), net 3,948 (1,675)
Non-cash GKE inventory step-up amortization 0 778
Nonoperating expense, net 3,948 (1,675)
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]    
Revenues (a): [1] 59,543 58,170
Depreciation in cost of revenues 810 862
Amortization in cost of revenues 702 647
Other cost of revenues (b) [2] 21,092 18,634
Total segment cost of revenues 22,604 20,921
Gross Profit (c) [3] 36,939 37,249
Operating expense 33,875 31,669
Operating income 3,064 5,580
Nonoperating (income), net (3,948) 1,675
Earnings before income taxes 7,012 3,905
Non-cash GKE inventory step-up amortization [4]   778
Nonoperating expense, net (3,948) 1,675
Sterilization and Disinfection Control [Member] | Operating Segments [Member]    
Revenues (a): [1] 25,410 [5] 22,957 [6]
Depreciation in cost of revenues 450 419
Amortization in cost of revenues 139 111
Other cost of revenues (b) [2] 6,655 6,091
Total segment cost of revenues 7,244 7,399
Gross Profit (c) [3] 18,166 15,558
Non-cash GKE inventory step-up amortization [7]   778
Biopharmaceutical Development [Member] | Operating Segments [Member]    
Revenues (a): [1] 11,486 12,008
Depreciation in cost of revenues 89 46
Amortization in cost of revenues 372 345
Other cost of revenues (b) [2] 4,719 3,658
Total segment cost of revenues 5,180 4,049
Gross Profit (c) [3] 6,306 7,959
Non-cash GKE inventory step-up amortization   0
Calibration Solutions [Member] | Operating Segments [Member]    
Revenues (a): [1] 12,350 11,801
Depreciation in cost of revenues 105 185
Amortization in cost of revenues 0 0
Other cost of revenues (b) [2] 5,203 4,374
Total segment cost of revenues 5,308 4,559
Gross Profit (c) [3] 7,042 7,242
Non-cash GKE inventory step-up amortization   0
Clinical Genomics [Member] | Operating Segments [Member]    
Revenues (a): [1] 10,297 11,404
Depreciation in cost of revenues 166 212
Amortization in cost of revenues 191 191
Other cost of revenues (b) [2] 4,515 4,511
Total segment cost of revenues 4,872 4,914
Gross Profit (c) [3] $ 5,425 6,490
Non-cash GKE inventory step-up amortization   $ 0
[1] Intersegment revenues are not significant and are eliminated to arrive at consolidated totals. Revenues as presented are consistent with GAAP measurement principles and our CODM's review of segment information.
[2] Other segment cost of revenues for each reportable segment includes product costs, personnel costs (including stock-based compensation), and other manufacturing and overhead costs necessary to produce and sell our products and services, excluding depreciation, amortization and any non-cash inventory step-up amortization expense.
[3] Gross profit as presented is consistent with GAAP measurement principles and our CODM's review of segment information.
[4] Unallocated corporate expenses and other business activities are reported within Corporate and Other. Certain depreciation expense classified reflected in Corporate and Other in fiscal years 2024 and 2023 has been recast to conform to current year presentation.
[5] Revenues of $24,815 from GKE are included in the Sterilization and Disinfection Control division during the year ended March 31, 2025.
[6] Revenues of $9,289 from GKE are included in the Sterilization and Disinfection Control division during the year ended March 31, 2024 and represent sales made beginning from the acquisition date.
[7] Includes GKE results beginning upon acquisition in fiscal year 2024.